Nazila Kamaly

Research in the Kamaly lab is highly multidisciplinary and focuses on the development of next-generation targeted controlled release polymeric nanomedicines for chronic inflammatory diseases such as atherosclerosis. We use bioinspired approaches to create multi-functional nanoparticles capable of changing their surface or core properties in response to local or up-regulated disease markers for more effective and smart stimuli-responsive drug delivery. We deliver in a spatiotemporally controlled manner, a range of potent biologic therapeutics from enzymes, proteins and peptides, with the aim of reducing systemic toxicity and collateral damage to the host. We are also interested in developing microfluidic and lab-on-a-chip systems as in vitro and ex vivo biomimetic models with controlled environmental parameters for testing our nanomedicines or gaining more improved biological mechanistic insight. We are inspired by innate biological pathways to design multifunctional bionanomaterials and to create nanotechnologies of the future to meet the needs of society. 



Nazila Kamaly
Gruppeleder, Lektor
DTU Sundhedsteknologi
45 25 81 52
22 APRIL 2019